"This partnership marks a transformational milestone in iX’s evolution from a research-focused innovation company into a commercial-stage enterprise with direct access to the world’s largest healthcare market," says iX Biopharma.
iX Biopharma, fresh from raising $6.7 million via a placement last month, plans to form a joint venture with a US-based drug maker Orion Speciality Labs to manufacture and commercialise its WaferiX portfolio.
By doing so, it will not need to go through additional clinical trials.
